NANTES, France--(BUSINESS WIRE)--Regulatory News:
OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) today reports it annual financial results as of December 31, 2016, and provides an update on the key achievements as well as the company’s outlook for its agonist and antagonist immunotherapies.
“We achieved significant progress in 2016, including securing two partnerships with world renowned pharmaceutical groups that ensure the focused development of our disruptive immunotherapies for auto-immune disorders.” said Dominique Costantini, CEO of OSE Immunotherapeutics. “In addition, we met key preclinical and clinical development goals for our immuno-oncology franchise specifically for our lead product Tedopi®, as well as OSE-172 (Effi-DEM). We intend to broaden our pipeline in immuno-oncology over the next few months, including for our most advanced clinical product, Tedopi®, which will be evaluated in combination with checkpoints inhibitors and in new cancer indications. Moreover, with financial results which, for the first time, show an annual net profit of 21 million euros and a financial visibility until the second half of 2018, the company is in a solid financial position to take the next steps of its growth.”
OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) today reports it annual financial results as of December 31, 2016, and provides an update on the key achievements as well as the company’s outlook for its agonist and antagonist immunotherapies.
“We achieved significant progress in 2016, including securing two partnerships with world renowned pharmaceutical groups that ensure the focused development of our disruptive immunotherapies for auto-immune disorders.” said Dominique Costantini, CEO of OSE Immunotherapeutics. “In addition, we met key preclinical and clinical development goals for our immuno-oncology franchise specifically for our lead product Tedopi®, as well as OSE-172 (Effi-DEM). We intend to broaden our pipeline in immuno-oncology over the next few months, including for our most advanced clinical product, Tedopi®, which will be evaluated in combination with checkpoints inhibitors and in new cancer indications. Moreover, with financial results which, for the first time, show an annual net profit of 21 million euros and a financial visibility until the second half of 2018, the company is in a solid financial position to take the next steps of its growth.”
